Full-Time

Manufacturing Solution Prep Manager

Nights

Updated on 9/13/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$106.1k - $143.6k/yr

+ 15% shift differential + Annual bonus + Stock-based long-term incentives

West Greenwich, RI, USA

In Person

Bachelor's, Master's, PhD, Associate's

Category
Biology & Biotech (1)
Required Skills
Supply Chain Management
Data Visualization
Process Engineering
GMP
Quality Assurance (QA)
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A high school diploma or GED and 12 years of Manufacturing and Operations experience, or an associate’s degree and 10 years of Manufacturing and Operations experience, or a bachelor’s degree and 5 years of Manufacturing and Operations experience, or a master’s degree and 3 years of Manufacturing and Operations experience, or a doctorate degree.
  • Experience directly managing people and/or leadership experience leading teams, projects, programs, or directing the allocation of resources.
  • Ability to work a 12-hour night shift from 7 p.m. to 7 a.m. on a two-week rotation covering seven days per week after onboarding.
  • Ability to champion a safe and compliant production environment and make timely decisions in a dynamic production environment.
Responsibilities
  • Lead on-the-floor manufacturing operations and staff with minimal direction.
  • Supervise, coach, hire, onboard, and develop manufacturing staff while ensuring team members are trained, capable, engaged, and prepared to meet production requirements.
  • Own and reinforce the safety and quality culture within the shift through active engagement and coaching.
  • Lead the shift and collaborate with peer managers to deliver production targets.
  • Coordinate daily task allocation and plan short- to mid-term schedule needs with the scheduling team.
  • Monitor department performance on the floor, provide coaching, and ensure consistency with Floor Operating Principles.
  • Coordinate with support functions to troubleshoot, identify, and resolve issues during the shift.
  • Build a high-performing team, ensure accountability, and advance technical and leadership capabilities.
  • Identify and drive process improvement initiatives to improve efficiency and eliminate non-value-added activities.
  • Plan and execute cross-training and dynamic resource allocation across AR5 and AR30.
  • Assist in developing and implementing departmental strategy and plans aligned with AR5, ARI, and site manufacturing objectives.
  • Translate strategic priorities into daily, weekly, and shift-level execution plans.
  • Anticipate operational, quality, safety, training, and schedule risks and build contingencies to reduce their impact.
  • Deliver business results through continuous improvement, standardization, and disciplined execution.
  • Use metrics, audit outcomes, process data, and staff feedback to identify trends and improve performance.
  • Lead change efforts that improve safety, compliance, quality, efficiency, throughput, and reliability.
  • Ensure the team understands how daily execution connects to Amgen’s mission, patient impact, and AR5 business priorities.
  • Be responsible for selection, onboarding, training, evaluation, staff relations, performance management, and development of manufacturing staff.
  • Ensure the appropriate people, skills, and resources are in place and allocated to achieve production, quality, and business goals.
  • Interact with management to optimize organizational structure, roles, responsibilities, and shift performance.
  • Build and develop a diverse team capable of reliably executing complex manufacturing operations.
  • Work across functions to build organizational and individual capability.
  • Provide staff members with open, clear, and actionable feedback.
  • Foster accountability, innovation, continuous improvement, learning, knowledge-sharing, and psychological safety.
  • Promote clear communication across shifts to ensure continuity, alignment, and readiness.
  • Lead with a people-centered approach supporting engagement, retention, empowerment, and development.
Desired Qualifications
  • A background in Life Sciences or Engineering.
  • Knowledge and experience in a cGMP or other highly regulated environment, including basic understanding of technical elements across engineering, biological, or chemical processing.
  • Skill in change management, team building, and fostering innovation.
  • Communication, drive, sense of urgency, and analytical problem-solving abilities.
  • Experience applying Operational Excellence and Lean Manufacturing.
  • Experience with performance management, including coaching, conflict resolution, and performance reviews.
  • Flexibility and ability to manage change.
  • Ability to forge and maintain strong relationships with other functional areas.
  • User-level fluency with digital tools for daily management, data analysis and visualization, and applications of Artificial Intelligence such as Copilot and ChatGPT.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
  • Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
  • MariTide now has nine ongoing and three planned Phase 3 studies across obesity.

What critics are saying

  • Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
  • FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
  • If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.

What makes Amgen unique

  • Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
  • IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
  • Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.